Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
-
- STATUS
- Recruiting
-
- End date
- Mar 31, 2025
-
- participants needed
- 25
-
- sponsor
- University of California, San Francisco
Summary
This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib may help treat patients with KIT-mutant melanoma.
Description
PRIMARY OBJECTIVE:
I. To evaluate the overall response rate (ORR) of binimetinib plus imatinib in patients with advanced KIT-mutant melanoma.
SECONDARY OBJECTIVES:
I. To determine the safety and tolerability of binimetinib plus imatinib in patients with advanced KIT-mutant melanoma.
II. To estimate efficacy and survival parameters in patients with advanced KIT-mutant melanoma treated with binimetinib plus imatinib.
III. To estimate efficacy in patients with advanced KIT-mutant melanoma treated with binimetinib plus imatinib.
EXPLORATORY OBJECTIVES:
I. To investigate association between changes in drug phosphorylated end products (p-KIT, p-MEK, p-ERK) and clinical response.
II. To investigate association between clinical response and baseline Neurofibromatosis 1 (NF1) and SPRED1 status.
III. To investigate pathologic correlates of acquired resistance. IV. To investigate whether NF1 and SPRED1 loss contribute to acquired resistance.
V. To generate patient-derived xenograft models. VI. To determine the relationship between clinical outcomes and clinicopathologic features including KIT exon mutated, melanoma subtype, melanoma primary site, race/ethnicity, prior treatment history including immune checkpoint inhibitor (ICI)-experienced versus (vs) - naive.
- OUTLINE
Patients receive binimetinib orally (PO) twice daily (BID) on days 1-28 and imatinib PO once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at day 30 and 100, and then every 3 months.
Details
| Condition | Melanoma Stage III, Melanoma Stage IV |
|---|---|
| Treatment | Imatinib, Binimetinib |
| Clinical Study Identifier | NCT04598009 |
| Sponsor | University of California, San Francisco |
| Last Modified on | 28 December 2021 |
Eligibility
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer